Tigecycline
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious
Trial Timeline
Jul 1, 2006 → Aug 1, 2007
NCT ID
NCT00488761About Tigecycline
Tigecycline is a approved stage product being developed by Pfizer for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00488761. Target conditions include Skin Diseases, Infectious.
What happened to similar drugs?
7 of 20 similar drugs in Skin Diseases, Infectious were approved
Approved (7) Terminated (7) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01560143 | Approved | Completed |
| NCT01401023 | Pre-clinical | Completed |
| NCT01072539 | Pre-clinical | Completed |
| NCT00827541 | Pre-clinical | Completed |
| NCT00575094 | Phase 3 | Completed |
| NCT00419991 | Approved | Completed |
| NCT00406237 | Phase 1 | Completed |
| NCT00488488 | Pre-clinical | Completed |
| NCT00376324 | Phase 1 | Completed |
| NCT00488306 | Approved | Completed |
| NCT00488761 | Approved | Completed |
| NCT00136201 | Phase 3 | Completed |
| NCT00205816 | Phase 3 | Completed |
| NCT00079989 | Phase 3 | Completed |
| NCT00079885 | Phase 3 | Completed |
| NCT00079976 | Phase 3 | Completed |
| NCT00081744 | Phase 3 | Completed |
| NCT00600600 | Phase 2 | Completed |
Competing Products
20 competing products in Skin Diseases, Infectious